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Abstract
Arthritic diseases are a major cause of disability and morbidity, and cause an enormous burden
for health and social care systems globally. Osteoarthritis (OA) is the most common form of
arthritis. The key risk factors for the development of OA are age, obesity, joint trauma or
instability. Metabolic and endocrine diseases can also contribute to the pathogenesis of OA.
There is accumulating evidence to suggest that OA is a whole-organ disease that is influenced
by systemic mediators, inflammaging, innate immunity and the low-grade inflammation
induced by metabolic syndrome. Although all joint tissues are implicated in disease progression
in OA, articular cartilage has received the most attention in the context of aging, injury and
disease. There is increasing emphasis on the early detection of OA as it has the capacity to
target and treat the disease more effectively. Indeed it has been suggested that this is the era of
‘‘personalized prevention’’ for OA. However, the development of strategies for the prevention
of OA require new and sensitive biomarker tools that can detect the disease in its molecular
and pre-radiographic stage, before structural and functional alterations in cartilage integrity
have occurred. There is also evidence to support a role for biomarkers in OA drug discovery,
specifically the development of disease modifying osteoarthritis drugs. This Special Issue of
Biomarkers is dedicated to recent progress in the field of OA biomarkers. The papers in this
Special Issue review the current state-of-the-art and discuss the utility of OA biomarkers as
diagnostic and prognostic tools.
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Introduction
The musculoskeletal system consists of the muscular and
skeletal elements that support the weight of the body,
maintain position and produce controlled and precise move-
ments, thus facilitating locomotion. It includes bones,
muscles, tendons and ligaments, articular cartilage and
intervertebral discs in the spine. The musculoskeletal
disorders (MSDs) represent a large variety of conditions
that affect muscles, bones, joints and the spine. MSDs are
caused by a number of factors including age, occupation,
activity level and lifestyle, which are influenced by eating
behavior and diet. The prevalence of MSDs is gradually
increasing; an estimated 15% of Americans (40 million
people) had some form or arthritis in 1995 and by the year
2020 it is estimated that 18.2% Americans (59.4 million
individuals) will be affected (Lawrence et al., 1998). Arthritic
diseases of synovial joints are some of the most common
MSDs and the most common form of arthritis is osteoarthritis
(OA). OA represents a major cause of disability and
morbidity, and causes an enormous burden for health and
social care systems globally. In the Global Burden of Disease
2010 study, hip and knee OA was ranked as the 11th highest
contributor to global disability (Cross et al., 2014). The
prevalence of OA is set to increase in parallel with the
increase in the number of people aged 60 years and older and
the rise in obesity across the world. Cohort studies have
demonstrated that after age, obesity and metabolic disease are
major risk factors for the development of OA (Aspden et al.,
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2001; Felson et al., 1988). OA is now accepted to be a whole-
organ disease that is influenced by obesity (Bliddal et al.,
2014), synovitis (De Lange-Brokaar et al., 2012), complement
proteins (Wang et al., 2011), systemic inflammatory medi-
ators (Berenbaum, 2013; Liu-Bryan & Terkeltaub, 2014),
inflammaging (Greene & Loeser, 2015; Mobasheri et al.,
2015), innate immunity (Orlowsky & Kraus, 2015) and the
low-grade inflammation (Sellam & Berenbaum, 2013)
induced by metabolic syndrome (Berenbaum, 2013;
Courties et al., 2015) and diabetes mellitus (Louati et al.,
2015). Inversely, OA is a risk factor for metabolic syndrome
and cardiovascular diseases, suggesting that effective treat-
ment of OA may prevent or delay the development of a large
number of associated comorbidities (Haugen et al., 2013;
Prior et al., 2014). However, despite the fact that all joint
tissues are implicated in disease progression in OA, it is the
articular cartilage component that has received the most
attention in the context of aging, injury and disease
(Buckwalter & Mankin, 1998).
Articular cartilage is a load-bearing connective tissue that
serves as a template for the development of skeletal elements
during embryogenesis (Archer & Francis-West, 2003) and is
responsible for the smooth and friction-free joint articulation
in synovial joints (Sandell, 2012). However, articular cartilage
has a limited capacity for self-repair because of its avascular
nature (Buckwalter & Mankin, 1998) and the low prolifer-
ation rate of chondrocytes, the main cells responsible for its
physiological maintenance (Sandell & Aigner, 2001).
Chondrocytes are the resident cell of the cartilage extracel-
lular matrix (ECM). They exist in a unique niche that consists
of collagen Type II, large aggregating proteoglycans (e.g.
aggrecan), glycosaminoglycans, hyaluronan, other non-col-
lagenous proteins (e.g. cartilage oligomeric matrix protein
(COMP)), and a large amount of water and mobile cations
(i.e. Na+, K+, Ca2+); this composition allows cartilage to
resist biomechanical forces during joint loading and physical
activity (Jahr et al., 2015b).
Biomarkers
The National Institutes of Health (NIH) Biomarkers
Definitions Working Group has defined a biomarker as ‘‘a
characteristic, i.e. objectively measured and evaluated as an
indicator of normal biological processes, pathogenic pro-
cesses or pharmacologic responses to a therapeutic interven-
tion’’ (Biomarkers Definitions Working Group, 2001). In
essence biomarkers help healthcare professionals to diagnose
illness, measure its progress and check how well novel or
preexisting treatments work. Important biomarkers include:
 Biomarkers that help us to diagnose illness
 Biomarkers that help us to predict illness or
 Biomarkers that allow us to assess a patient’s physical
condition.
Approximately 10 years ago it became apparent that the
OA researchers needed a definition of biomarkers for their
own community. Accordingly, the NIH-funded OA
Biomarkers Network was assembled. The group published
an article in 2006 that summarized efforts to characterize and
classify OA biomarkers. The group proposed the ‘‘BIPED’’
biomarker classification, which stands for Burden of Disease,
Investigative, Prognostic, Efficacy of Intervention and
Diagnostic (Bauer et al., 2006). The ‘‘BIPED’’ classification
was subsequently revised to BIPEDs include ‘‘safety’’. Use of
this classification system has been encouraged to communi-
cate these advances within a common framework and make
OA biochemical marker research more transparent and
efficient (Lafeber & van Spil, 2013), offering suggestions
on optimal study design and the development of analytical
methods for use in OA focused investigations (Bauer et al.,
2006).
We now have an extensive list of OA biomarkers and
efforts are currently under way to use some of these markers
to identify sub-clinical and/or sub-acute inflammation, par-
ticularly in scenarios that are relevant to the clinical setting
(Daghestani & Kraus, 2015). Consequently, there has been a
significant change in our perception of OA, exemplified in a
large shift in our outdated understanding of OA as a ‘‘wear
and tear’’ disease to an inflammatory disease (Berenbaum,
2013; Daghestani & Kraus, 2015).
Biomarkers of joint disease
Although radiographs and other types of joint imaging are
routinely used as ‘‘gold standard’’ diagnostic techniques for
joint diseases (Braun & Gold, 2012), they do not have the
capacity to measure dynamic changes in the joint. The
diagnosis of OA is generally based on clinical and radio-
graphic changes, which occur very late during the disease
pathogenesis pathway and have poor sensitivity for monitor-
ing disease progression (Rousseau & Delmas, 2007, Rousseau
& Garnero, 2012). There are numerous different biochemical
markers that can be measured in body fluids such as serum,
urine and synovial fluid to complement biomedical imaging
(Rousseau & Garnero, 2012). Biochemical markers or ‘‘wet’’
biomarkers can complement imaging and visual analog scales
also known as ‘‘dry’’ biomarkers (Henrotin, 2012). Research
conducted over the last four decades has demonstrated that
the cartilage ECM is a rich source of biomarkers in joint
diseases and many of these are now becoming established in
the research community (Hedbom et al., 1992; Lohmander
et al., 1994; Lotz et al., 2013). The maintenance of the ECM
is compromised in aging, injury and disease and ECM
components are degraded by catabolic enzymes in response to
inflammatory mediators, producing ‘‘fragments’’ that are
released into synovial fluid and the general circulation
(Chockalingam et al., 2011). Although the identification of
such fragments in synovial fluid, serum and urine does not
consistently correlate with radiographic changes and symp-
toms such as pain and loss of mobility, fragments of Type II
collagen, aggrecan and smaller proteoglycans can be
measured as indicators or ‘‘biomarkers’’ of early joint disease
(Larsson et al., 2012). They reflect metabolic changes that
occur in joint tissues, which is an early and dynamic process
that cannot be investigated by use of conventional medical
imaging techniques. There is increasing emphasis on better
characterization of early OA phenotypes and the early
detection of molecular alterations in articular cartilage as
this approach has the capacity to treat and target the disease
more effectively (Conaghan, 2013). Indeed it has been
suggested that this is the era of ‘‘personalized prevention’’
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for OA (Roos & Arden, 2015). However, the development of
strategies for the prevention of OA require new and highly
sensitive biomarker tools that can detect the diseases in its
molecular and pre-radiographic stage, long before structural
and functional alterations in tissue integrity have occurred.
However, finding biomarkers with the sensitivity and speci-
ficity to achieve this remains a challenging problem
(Mobasheri, 2012). Although many laboratories are actively
involved in identifying and developing new diagnostic and
prognostic biomarkers of OA, radiographic imaging remains
the ‘‘gold standard’’ for assessment of disease progression in
OA and other forms of degenerative joint disease (Lotz et al.,
2013).
Special issue: biomarkers of arthritis
This Special Issue will focus on recent progress in the field of
OA biomarkers and their utility as diagnostic and prognostic
tools. The content of some of the key papers in this Special
Issue is summarized below.
As discussed earlier obesity is associated with an increased
risk of developing OA, even in non-weight bearing
joints. High levels of adipose tissue-associated cytokines
may explain this association (Kluzek et al., 2015a).
Stefan Kluzek, Nigel Arden and Julia Newton from Nuffield
Department of Orthopaedics, Rheumatology and
Musculoskeletal Sciences at the University of Oxford discuss
the role of adipokines as potential prognostic biomarkers in
patients with acute knee injury. Recent data suggests that
adipokines produced by white adipose tissue, such as leptin,
may provide a mechanistic link between obesity and OA,
providing an explanation for the high prevalence of OA
among obese and over-weight individuals (Scotece &
Mobasheri, 2015). In their review Kluzek et al. discuss the
role of leptin, resistin and vistfatin as key mediators of
catabolic pathways associated with cartilage degeneration.
Their article considers adipokines as predictive biomarkers
for early onset post-traumatic knee osteoarthritis (Kluzek
et al., 2015b).
In their article entitled: ‘‘Chopping off the chondrocyte
proteome’’ Mona Dvir-Ginzberg and Eli Reich from the
Hebrew University in Jerusalem discuss the biomarkers
generated from chondrocytes upon increased protease activ-
ity. Specifically, they discuss the role of degraded and cleaved
cellular proteins, rather than ECM fragments as less abundant
biomarkers that may nevertheless exert significant adverse
effects on cell metabolism and the cartilage secretome. They
propose that subtle changes in the chondrocyte secretome
could potentially act as markers of altered metabolism. They
propose that combined biomarkers from both cell and ECM-
degraded secretomes could provide a valuable platform for
testing drug efficacy to halt OA progression during early
stages (Dvir-Ginzberg & Reich, 2014).
‘‘Big data’’, machine learning and computational methods
are starting to make an impact in the areas of chondrocyte
biology (Henrotin et al., 2010) and OA biomarkers (Swan et al.,
2015). Investigations into novel OA biomarkers using OMICS
techniques generate large amounts of data. Due to their size
and numbers of attributes, these data are suitable for analysis
with machine learning methods. Roman Krawetz & Guomin
Ren (2015) discuss the potential for applying computational
biology and ‘‘big data’’ approaches to develop and refine
multiplex diagnostics for complex chronic diseases such
as OA.
In his State of the Union Address on 20 January 2015
President Barack Obama launched a new initiative on
‘‘Precision Medicine’’ [reviewed by Collins and Varmus
(Collins & Varmus, 2015)]. Precision medicine is the
preferred new term used to describe targeted and personalized
approaches for treating chronic diseases. The article by Yves
Henrotin et al. (2015) discusses the importance of soluble
biomarkers in the development of personalized medicine
strategies for OA.
Synovitis is another important and emerging risk factor for
the development and progression of OA (Felson et al., 2015;
Scanzello & Goldring, 2012). Interestingly, synovitis has hit
the news several times over the last few years. In February
2013 Lady Gaga canceled the rest of her Born This Way Ball
world tour because she developed debilitating synovitis1,2.
She was unable to perform on stage due to severe joint
inflammation and had to undergo surgery. In this Special
Issue, Cecilie Kjelgaard-Petersen and her colleagues (2015) at
Nordic Bioscience developed an ex vivo culture model of
synovitis to characterize three biomarkers of inflammatory
OA. It is hoped that further work on synovitis models will
identify early marker of synovial inflammation, which is a
key target for early intervention in OA.
In a second article in this Special Issue, Stefan Kluzek and
coauthors (2015c) focus on serum COMP and how it levels
correlate with the development of radiographic and painful
knee OA in a community-based cohort of middle-aged
women. Serum COMP appears to be a promising biomarker
but further research is needed to further understand the
association between COMP and long-term outcomes in this
population.
Vanessa Abella and colleagues discuss the potential of
Lipocalin2/NGAL as biomarker for inflammatory and meta-
bolic diseases. LCN2 has emerged as a useful biomarker and
rheumatic diseases. Their review provides an overview of
LCN2 in inflammation, immunity, and metabolism (Abella
et al., 2015).
Despite the fact that many drug targets reside on the
plasma membrane there is insufficient knowledge about the
chondrocyte membranome and its molecular composition.
Csaba Matta and coauthors (2015) contribute an original
research article that reports a modified phase partitioning
technique for profiling integral membrane proteins in primary
articular chondrocytes. The method uses an optimized Triton
X-114 phase partitioning technique and LC-MS/MS analysis
for protein identification. The method yielded a high propor-
tion of membrane proteins (56%) including CD276, S100-A6
and three voltage-dependent anion channel isoforms. Defining
the chondrocyte membranome is likely to reveal new
biomarker targets for conventional and biological drug
discovery.
1http://www.theweek.co.uk/health-science/51499/lady-gaga-cancels-
gigs-due-inflamed-joint-condition
2http://www.huffingtonpost.com/2013/02/13/synovitis-lady-gaga-health-
inflammation-joints_n_2678387.html
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Finally, Holger Jahr and colleagues (2015a) contribute
their perspective on detecting OA by optical coherence
tomography (OCT), an emerging technology for performing
high-resolution cross-sectional imaging. OCT is analogous to
ultrasound imaging, except that it uses light instead of sound.
Since many MSDs such as OA are associated with irreversible
bone and cartilage damage, a clinical need exists for the
development of imaging modalities that can detect structural
changes at an early stage (Rashidifard et al., 2013). OCT may
turn out to be a complementary technique for early OA
diagnosis.
Conclusions
Biomarkers provide useful diagnostic information by
detecting cartilage degradation in OA, reflecting disease-
relevant biological activity and predicting the course of
disease progression. They also serve as complementary
endpoints in the drug discovery process (Mobasheri, 2012)
(Figure 1). As such, biomarkers of joint tissue turnover
(i.e. ECM fragments), cytokines and chemokines continue
to be measured in different cohorts and community
studies. This makes them highly complementary tools to
imaging and visual analog scales for measuring pain
symptoms. However, there is still a huge and unmet
medical need to identify, test, validate and qualify novel
and well-known biomarkers (Bay-Jensen et al., 2016;
Hunter et al., 2014). Combining biochemical markers
with tissue and cell imaging techniques and bioinformatics
may facilitate the development of biomarker combinations
enabling earlier detection of OA (Mobasheri, 2012). There
is increasing evidence to support a role for biomarkers in
drug development for OA (Mobasheri, 2013a,b). Various
OMICs approaches and technologies are being used to
identify new biomarkers and validate existing biomarkers,
thus contributing to our understanding of joint disease
development, progression and responses to therapy. The
ultimate aim of these ongoing efforts is to develop
surrogate and complementary endpoints in large-scale
clinical trials and facilitate the discovery of disease
modifying osteoarthritis drugs. There are recent guidelines
from the Food and Drug Administration and the European
Medicines Agency on qualification and usage of bio-
markers for drug development and personalized medicine.
These guidelines are likely to impact the design and
implementation of future studies. The development of new
and more sensitive analytical techniques for the identifi-
cation of OA biomarkers will lead to further progress in
this field. It should also be strongly emphasized that
biomarkers reflect metabolic changes in joint tissues and
that metabolic responses should be considered in addition
to symptomatic or structural responses. Future papers on
this topic will need to address some of the following
questions:
 How can basic research in cartilage biology, chondrocyte
physiology and ECM-derived biomarkers contribute to
our understanding of OA?
 What is the rationale for identifying new biomarkers of
OA and can current analytical platforms be refined to
improve sensitivity and specificity?
 Can biomarkers help us define ‘‘early’’, ‘‘pre-radio-
graphic’’ OA?
 How can biomarkers be used as drug development tools
and surrogate end-points in OA clinical trials?
Researchers in the field of OA biomarkers must continue
to tackle these challenging issues. They also need to decide
whether the current definitions are fit for purpose. Perhaps
future research in this area will need to adopt a broader
Figure 1. Applying the biomarker toolbox in
the drug discovery and development pathway.
This schematic highlights the mutual inter-
dependency of the drug and biomarker
development pipelines. Linking a biomarker
to a complementary endpoint facilitates the
drug discovery process and allows pharma-
ceutical companies to make rational decisions
about the continuity of preclinical studies and
clinical trials. Biomarkers can be used at
critical decision points to make go/no-go
decisions. They can also be used in transla-
tional research, bridging the gap between the
bench and the bedside. Biomarkers can also
be used to identify responders and non-
responders and quantify clinical efficacy and
patient stratification (i.e. identification of
those in need of treatment and selection of
patients most likely to respond to treatment).
In phase II clinical trials biomarkers can be
used for dose determination and safety/effi-
cacy studies. They can also help pharma-
ceutical companies save costs by enabling
drug repositioning and determining the cost/
benefit ratio for treatment. In routine clinical
practice biomarkers are important diagnostic
and prognostic tools for monitoring disease
development and monitoring patients com-
pliance. They are also indispensable tools for
pharmacovigilance, personalized and preci-
sion health care and differentiating com-
pounds from competitors.
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definition of the term ‘‘biomarker’’ and develop risk predic-
tion tools that combine imaging, biochemical markers and
patient specific data including lifestyle and physical activity.
Such tools already exist in the form of FRAX, which assesses
fracture probability in men and women (Kanis et al., 2009). A
similar tool is needed for OA and biomarkers could poten-
tially become important components of a future OA risk
prediction tool.
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